Wedbush Equities Analysts Lift Earnings Estimates for FENC

Adherex Technologies Inc. (NASDAQ:FENC) – Research analysts at Wedbush upped their Q2 2026 EPS estimates for shares of Adherex Technologies in a research report issued on Friday, November 14th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of $0.39 for the quarter, up from their previous estimate of $0.37. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share.

FENC has been the topic of several other reports. Craig Hallum boosted their price target on shares of Adherex Technologies from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, August 15th. Zacks Research downgraded Adherex Technologies from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adherex Technologies in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Adherex Technologies in a research note on Thursday, August 21st. Finally, Wall Street Zen upgraded shares of Adherex Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Adherex Technologies has a consensus rating of “Hold” and a consensus target price of $13.33.

Adherex Technologies Price Performance

FENC opened at $8.75 on Monday. Adherex Technologies has a 1 year low of $4.00 and a 1 year high of $9.92. The company has a market capitalization of $246.02 million, a price-to-earnings ratio of -20.83 and a beta of 0.71. The firm’s fifty day moving average price is $8.67 and its two-hundred day moving average price is $8.35.

Adherex Technologies (NASDAQ:FENC) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.06. The company had revenue of $12.46 million during the quarter, compared to analysts’ expectations of $13.43 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC bought a new stake in shares of Adherex Technologies during the first quarter valued at about $2,199,000. Nuveen LLC purchased a new stake in Adherex Technologies in the 1st quarter worth approximately $158,000. Jane Street Group LLC bought a new position in Adherex Technologies in the 1st quarter valued at $90,000. Finally, AQR Capital Management LLC purchased a new position in shares of Adherex Technologies during the 1st quarter valued at $66,000. Institutional investors own 55.51% of the company’s stock.

Insider Transactions at Adherex Technologies

In related news, major shareholder Southpoint Capital Advisors Lp sold 160,100 shares of Adherex Technologies stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $8.00, for a total value of $1,280,800.00. Following the completion of the transaction, the insider directly owned 3,850,000 shares in the company, valued at approximately $30,800,000. The trade was a 3.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rosty Raykov sold 10,000 shares of the stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $8.10, for a total value of $81,000.00. Following the sale, the director owned 82,318 shares in the company, valued at approximately $666,775.80. This represents a 10.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 334,907 shares of company stock valued at $2,867,545 in the last quarter. Company insiders own 11.76% of the company’s stock.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.